IV vs. Sublingual Ketamine: Which Is More Effective?

What Is the Difference Between IV Ketamine and Sublingual Ketamine?

IV (intravenous) ketamine and sublingual ketamine deliver the exact same medicine through different routes of administration. IV ketamine enters the bloodstream directly through a needle in a medical setting. Sublingual ketamine comes as a tablet you hold between your cheeks and gums to absorb through the oral mucosa, typically at home.

Both methods use racemic ketamine. The FDA approved racemic ketamine as an anesthetic in 1970. The World Health Organization added the medicine to the List of Essential Medicines in 1985.¹

The practical differences between these methods shape your overall treatment experience. IV infusions require travel to a facility, the placement of an IV line, and in-person monitoring by a nurse or physician. At-home sublingual sessions eliminate travel and use a needle-free tablet. You complete the session in your own space with a remote provider and a required peer treatment monitor physically present. Sublingual therapy also costs significantly less per session than in-office IV treatments.

Comparison of Ketamine Delivery Methods

The core medical question is not which route is universally superior in the abstract. Instead, ask which approach produces the results you need within a defined treatment framework.

Is Sublingual Ketamine as Effective as IV Ketamine?

Within a supervised medical protocol, sublingual ketamine produces depression outcomes that sit within the response-rate range reported for IV ketamine in the peer-reviewed literature. The route of administration affects pharmacokinetics, which is how your body absorbs the medicine. Overall effectiveness is shaped by the full care model surrounding the medication.

Three main factors determine how well the treatment works for you.

Pharmacology Differences That Can Affect Results

Bioavailability refers to the percentage of a medication that reaches systemic circulation. Onset refers to how quickly the effects begin. IV ketamine reaches the bloodstream immediately with near-complete bioavailability. Sublingual ketamine is absorbed through the oral mucosa at a bioavailability of approximately 25 to 35 percent.⁶ Prescribing physicians calibrate dose to this absorption profile so each session delivers a therapeutic exposure within the same effective range as IV administration.

Onset is faster with IV administration, taking seconds to minutes, compared to 10 to 15 minutes for sublingual tablets.⁷ Providers account for these bioavailability differences through personalized dosing adjustments. The subjective intensity of a single session may differ between the two routes.

Regardless of how the medicine enters your body, the therapeutic mechanism is identical. Ketamine temporarily modulates neural communication by interacting with NMDA receptors and adjusting glutamate signaling between brain regions.² As a result, a temporary window of neuroplasticity opens, allowing your brain to form new, healthier pathways. Bioavailability is simply a pharmacokinetic variable that specialists manage through dose calibration, not a ceiling on your therapeutic potential.

Treatment Setting and Support That Can Affect Results

In psychedelic-assisted therapy, "set and setting" refers to your mindset and your physical environment. Your mindset includes your preparation, expectations, and emotional readiness. Your physical environment involves the comfort, safety, and familiarity of the space where treatment occurs. These factors shape how your brain processes the experience and integrates insights afterward.

IV sessions take place in a facility with medical staff present. At-home sessions take place in your own space with a required peer treatment monitor present to ensure safety. Research consistently identifies set and setting as a meaningful variable in therapeutic response.

Treating at home eliminates the clinical-environment stressors some patients find activating, lets the post-session period begin in your own bed, and creates space to process the experience privately. In-office settings offer immediate medical proximity, which may be the right fit for individuals whose screening identifies cardiovascular or psychiatric considerations that warrant on-site monitoring. What matters most is whether the protocol includes preparation, real-time support, and post-session integration. A well-designed at-home protocol with physician oversight can match or complement the advantages of an in-office setting.

Mindbloom Outcomes Data From Peer-Reviewed Studies

Building on decades of research on ketamine's therapeutic applications, Mindbloom has published two of the largest peer-reviewed, real-world outcomes studies of at-home ketamine therapy to date. These studies, published in the Journal of Affective Disorders, evaluate safety and effectiveness at scale. Mindbloom's published at-home sublingual studies reported response rates within the range described in IV ketamine literature, although cross-study comparisons should be interpreted cautiously because study design, patient populations, and outcome measures differ.

For depression, 89% of clients reported symptom improvement. In Mindbloom's peer-reviewed studies, response rates ranged from 56 to 63%.^3,4 The findings come from a study of 11,441 patients and a separate study of 1,247 patients, measured using the validated PHQ-9 instrument. For anxiety, 89% of participants reported improvement. The data showed a 56.1% response rate measured via the GAD-7.

These response rates sit within the range reported in IV ketamine meta-analyses of treatment-resistant depression.⁵ Two contextual notes: Mindbloom's response data is measured across multiple weeks of treatment, while most published IV ketamine response rates are measured at 24 hours to 7 days post-infusion; and Mindbloom's cohorts (11,441 and 1,247 patients) are substantially larger than the trial sizes that anchor the IV literature.^3,4 Individual results may vary.

What to Expect During IV Infusion Ketamine vs At-Home Sublingual Sessions

Both formats deliver the same molecule through a supervised protocol, but the daily logistics look very different. A typical IV infusion visit requires travel to a facility, checking in, and having an IV line placed in your arm. The infusion lasts 40 to 60 minutes, during which a nurse or physician monitors you in person. Afterward, you complete an observation period in the office and must have someone drive you home.

A typical at-home sublingual session begins with preparation in your own familiar space. You hold a tablet between your cheeks and gums for approximately 7 minutes before spitting it out. Effects begin within 10 to 15 minutes. The session is guided by an app-based program featuring custom soundscapes. Your required peer treatment monitor (described above) remains present throughout. Your care team is available remotely for ongoing support.

Here is how the two formats compare in practice:

• Session duration: IV appointments often take two hours including observation, while at-home sessions take about 60 to 90 minutes.
• Logistics: At-home care eliminates commute times and scheduling constraints.
• Comfort level: Sublingual tablets are needle-free and allow you to rest in your own bed or favorite chair.
• Cost: Sublingual therapy is approximately 60% less expensive per session than IV infusions. Mindbloom's at-home ketamine therapy ranges from $165 to $215 per session for new clients, depending on program length. A 6-session program costs $215 per session, billed in monthly installments of $430 for three months. Returning clients receive preferred pricing starting at $129 per session.
• Post-session period: For both methods, you must avoid driving until after a full night of sleep. Individual experiences vary for resuming other daily activities.

About Mindbloom's Program

Mindbloom offers programs of 6, 12, or 18 sessions. The program includes unlimited Group Integration Circles, the Bloombox experiential toolkit, and comprehensive app-guided programs.

Practically speaking, the differences come down to logistics: where you are, how the medicine enters your system, who is physically present, and what the session costs.

How Care Protocols Support Safety and Outcomes in At-Home Ketamine Therapy

A care protocol is the full system of screening, oversight, session support, and integration that surrounds the medicine. Safety and effectiveness in ketamine therapy are functions of this comprehensive system, not the administration route alone.²

The components of a safe and effective at-home program include:

• Medical screening and eligibility: A licensed provider conducts a comprehensive evaluation to confirm you are an appropriate candidate. Ketamine therapy may not be appropriate for individuals with uncontrolled hypertension, psychotic disorders, or active substance use disorders.
• Provider-determined dosing: Sub-anesthetic, therapeutic doses are personalized by the prescribing physician based on medical judgment and adjusted over time based on your response.
• Required peer treatment monitor: A trusted adult must be physically present during every session as part of the safety protocol.
• Preparation and integration: Dedicated preparation before each session and integration coaching afterward help you translate the neuroplastic window into lasting behavioral and emotional change.
• Ongoing medical oversight: Provider consults occur at defined intervals throughout the program to monitor progress and adjust the care plan.

After you select a program, this evaluation (described above) confirms your eligibility and personalizes your care plan. Mindbloom's care model includes provider consults, one-on-one guide coaching sessions, and unlimited guide messaging.

Safety data from Mindbloom's published research reinforces the effectiveness of this model. Side effects occur in approximately 4 to 5% of sessions. In Mindbloom's published study, serious adverse events occurred in fewer than 0.1% of sessions, and discontinuation was 0.4%.³ The care infrastructure around the medicine is a key factor in supporting safer delivery and clinically meaningful results in at-home ketamine therapy. Mindbloom's model is one of the most extensively studied implementations of this approach.

Conclusion

Within a supervised at-home protocol — screening, medical oversight, preparation, and integration — sublingual ketamine delivers depression outcomes that sit alongside IV ketamine in the peer-reviewed literature, with 89% of participants in Mindbloom's published studies reporting symptom improvement and sustained response rates of 56–63%. The quality and rigor of the program around the medicine drives outcomes more than the route. For most people weighing their options, sublingual ketamine offers outcomes in the same range as IV at roughly 60% lower cost per session, at home, and without a needle. IV infusions remain appropriate for individuals whose screening indicates a need for in-person medical proximity or who are continuing care with an existing infusion clinic.

Important Safety Information

Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information

Off-Label Use Disclosure

Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.